Myriad Genetics (MYGN) Stock Rating Upgraded by BidaskClub

Myriad Genetics (NASDAQ:MYGN) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Other equities analysts have also recently issued research reports about the stock. Leerink Swann reissued a “market perform” rating and issued a $31.00 price target on shares of Myriad Genetics in a research note on Monday, October 2nd. Deutsche Bank boosted their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, November 8th. Stephens set a $45.00 price target on shares of Myriad Genetics and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Morgan Stanley boosted their price target on shares of Myriad Genetics from $24.00 to $26.00 and gave the stock an “underweight” rating in a research note on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $30.09.

Shares of Myriad Genetics (MYGN) opened at $38.62 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. The firm has a market cap of $2,670.00, a P/E ratio of 26.09, a P/E/G ratio of 2.34 and a beta of 0.24. Myriad Genetics has a twelve month low of $15.15 and a twelve month high of $38.65.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. The business had revenue of $190.20 million for the quarter, compared to analyst estimates of $183.52 million. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. Myriad Genetics’s revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.23 EPS. analysts forecast that Myriad Genetics will post 1.05 earnings per share for the current fiscal year.

In other news, insider Alexander Ford sold 3,031 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $31.64, for a total value of $95,900.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Walter Phd Gilbert sold 7,500 shares of the company’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $33.19, for a total transaction of $248,925.00. The disclosure for this sale can be found here. Insiders sold a total of 33,410 shares of company stock valued at $1,163,524 in the last ninety days. 6.70% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. GHP Investment Advisors Inc. boosted its stake in shares of Myriad Genetics by 11.1% in the 3rd quarter. GHP Investment Advisors Inc. now owns 48,710 shares of the company’s stock valued at $1,762,000 after purchasing an additional 4,853 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Myriad Genetics by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock valued at $162,992,000 after purchasing an additional 56,708 shares in the last quarter. PDT Partners LLC purchased a new stake in shares of Myriad Genetics in the 2nd quarter valued at $8,481,000. Shell Asset Management Co. boosted its stake in shares of Myriad Genetics by 34.3% in the 3rd quarter. Shell Asset Management Co. now owns 54,867 shares of the company’s stock valued at $2,116,000 after purchasing an additional 14,021 shares in the last quarter. Finally, Prudential Financial Inc. boosted its stake in shares of Myriad Genetics by 3.9% in the 3rd quarter. Prudential Financial Inc. now owns 131,073 shares of the company’s stock valued at $4,742,000 after purchasing an additional 4,900 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Myriad Genetics (MYGN) Stock Rating Upgraded by BidaskClub” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://stocknewstimes.com/2018/01/20/myriad-genetics-mygn-stock-rating-upgraded-by-bidaskclub.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply